AstraZeneca-Daiichi breast cancer drug cleared for NHS use in England

AstraZeneca and Daiichi Sankyo's breast cancer therapy Enhertu was approved for use in England's state-run healthcare system, expanding patient access beyond Scotland, where it has been available since 2023. The decision broadens the addressable market for Enhertu in the UK and is a positive commercial and clinical-access milestone for both companies.